Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Authors' conclusion
Based on this analysis, only half of those starting another ULT achieved target SU.
Study context
- Population
- Gout patients who discontinued pegloticase (gap ≥ 12 weeks after last infusion), Rheumatology Informatics System for Effectiveness (RISE) registry, 1/2016 to 6/2022
- Participants
- 375 patients
- Exposure
- On-treatment vs post-treatment lab values
- Outcome
- ULT use, SU, inflammatory biomarkers (CRP, ESR) and renal function (eGFR) following pegloticase discontinuation
Methodological detailsregistry-based (RISE registry)
- Registry-based (RISE registry)
Main finding
As reported in the abstract
Median (IQR) laboratory changes following discontinuation
- Serum urate (SU) change, mg/dL, median (IQR)
- +2.4 (0.0,6.3)
- eGFR change, mL/min, median (IQR)
- −1.9 (- 8.7,3.7)
- CRP change, mg/L, median (IQR)
- −0.8 (−12.8,0.0)
- ESR change, mm/hr, median (IQR)
- −4.0 (−13.0,0.0)
- Oral ULTs post-discontinuation
- 86.0%
- Restarting pegloticase
- 4.5%
- No documentation of ULT
- 9.5%
Observational data: associations, not effects.
Further findings
Oral ULT type following pegloticase
- Allopurinol
- 62.7%
- Febuxostat
- 34.1%
Time to starting/restarting ULT, median (IQR)
- Days
- 92.0 (55.0,173.0)
SU < 6 mg/dL following ULT prescribing (≥ 30 days)
- Patients with SU < 6 mg/dL
- 51.0%
Patients restarting pegloticase
- Median SU, mg/dL (IQR)
- 0.9 (0.2,9.7)
- SU < 6 mg/dL
- 58.3%
Original publication
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. Arthritis Res Ther. Published 12 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →